Tier B · Substantial human research
Thymosin Alpha-1
A peptide with decades of human immunology research—and mixed results depending on the disease.
Why researchers care
Potential human relevance
- Modulates innate and adaptive immune signaling
- Has been studied in chronic viral disease, cancer adjunct settings, pancreatitis and sepsis
- Some randomized studies reported immune-function or infection-related improvements
What the human evidence says
Evidence, not extrapolation
Thymosin alpha-1 has far more human data than most popular research peptides, but results vary by condition. A large recent sepsis trial did not show a clear mortality benefit.
How to think about it
The Yooper Peptides take
The lesson is nuance: “immune support” is not a single outcome. A peptide can change immune markers without automatically improving every clinical endpoint.
Primary / authoritative reading